Please login to the form below

Not currently logged in
Email:
Password:

vinflunine

This page shows the latest vinflunine news and features for those working in and with pharma, biotech and healthcare.

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

Keytruda, Opdivo narrow Tecentriq's lead in bladder cancer

The trial compared Keytruda to the investigator's choice of chemotherapy agents - paclitaxel, docetaxel or vinflunine - and showed that Merck's drug improved both progression-free survival (PFS) and overall survival.

Latest news

  • BMS abandons Pierre Fabre bladder cancer drug

    BMS and Pierre Fabre Medicament terminate their license agreement for the development of metastatic bladder cancer chemotherapy agent, vinflunine. ... US-based Bristol-Myers Squibb and France-headquartered Pierre Fabre Medicament have terminated their

  • Sanofi-aventis and BMS move closer toward merger

    BMS' oncology portfolio is also set to expand, with three oncology drug launches over the next two years: BMS 247550 (ixabepilone), MDX-010 (ipilimumab) and Javlor (vinflunine).

More from news
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
The Good Ideas Group

Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...

Latest intelligence

Sharing patient stories for World Pulmonary Hypertension Day
For World Pulmonary Hypertension Day and we’re here to help raise awareness of pulmonary hypertension (PH) - a frequently under and misdiagnosed condition. Created in collaboration with the PH patient...
How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...